{"product_id":"atnm-vrio-analysis","title":"Actinium Pharmaceuticals, Inc. (ATNM): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to Actinium Pharmaceuticals, Inc. (ATNM)'s market position starts here: this VRIO analysis cuts straight to the chase, evaluating its Value, Rarity, Inimitability, and Organization to pinpoint the source of any sustainable competitive advantage. See immediately what makes this business truly unique and resilient - or where strategic improvements are essential - by reading the full breakdown below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eActinium Pharmaceuticals, Inc. (ATNM) - VRIO Analysis: Iomab-B Clinical Data and Regulatory Position\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the core asset, Iomab-B, through the VRIO lens to see where Actinium Pharmaceuticals, Inc. stands right now. Honestly, the clinical win is huge, but the regulatory hurdle is the immediate focus for any decision-maker.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Positive Pivotal Phase 3 SIERRA Trial Results\u003c\/h3\u003e\n\u003cp\u003eThe positive pivotal Phase 3 SIERRA trial results for Iomab-B definitely deliver value by offering a less toxic conditioning agent for bone marrow transplants (BMT), which addresses a major unmet need for patients aged $\\mathbf{55+}$ with relapsed\/refractory Acute Myeloid Leukemia (AML). The trial met its primary endpoint, showing that $\\mathbf{22\\%}$ ($\\mathbf{13}$ out of $\\mathbf{76}$ patients) in the Iomab-B arm achieved a durable Complete Remission (dCR) of 6 months post-BMT, compared to $\\mathbf{0\\%}$ ($\\mathbf{0}$ out of $\\mathbf{77}$ patients) in the conventional care arm, with a statistical significance of $\\mathbf{p\u0026lt;0.0001}$. Also, Event Free Survival (EFS) improved significantly, with a Hazard Ratio of $\\mathbf{0.22}$ ($\\mathbf{p\u0026lt;0.0001}$). This is a clear, quantifiable benefit over current standard approaches for this niche patient group.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Significant, But Not Unique, Phase 3 Data\u003c\/h3\u003e\n\u003cp\u003eHaving positive Phase 3 data for a conditioning agent is a significant asset in this specialized area, but it isn't entirely unique in the broader landscape of oncology development. The data package itself is rare because it specifically addresses the dCR endpoint in this population. Still, the market has other conditioning agents, so the rarity comes from the quality and nature of the positive outcome, not the existence of an alternative.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Uniqueness of the Data Package vs. Agent Development\u003c\/h3\u003e\n\u003cp\u003eThe specific data package from the SIERRA trial, showing $\\mathbf{22\\%}$ dCR versus $\\mathbf{0\\%}$ in the control group, is unique to Iomab-B. However, the underlying technology - a CD45 targeted radiotherapy - is something competitors could aim to replicate with similar agents or novel conditioning regimens. What this estimate hides is the time and capital required for a competitor to generate comparable Phase 3 evidence.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Strategic Partner Search and Financial Position\u003c\/h3\u003e\n\u003cp\u003eActinium Pharmaceuticals, Inc. is showing organization by actively seeking a strategic partner to advance U.S. commercialization, recognizing the need for significant resources to navigate the next steps. As of June 30, 2025, the company held cash and cash equivalents of $\\mathbf{\\$59,928}$ thousand, which is crucial for ongoing operations while they secure a deal. However, the operating margin for the three months ended June 30, 2025, was a concerning $\\mathbf{-41,486.67\\%}$, underscoring why a partnership is an immediate strategic priority to fund the required additional trial.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on their current standing:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMetric (as of Q2 2025)\u003c\/td\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eContext\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCash \u0026amp; Equivalents (June 30, 2025)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e\\$59.93 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eLiquidity buffer for operations.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMarket Capitalization (Nov 2025)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e\\$45.23 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eReflects market valuation alongside development risk.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOperating Margin (3 Months Ended Q2 2025)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e-41,486.67%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eSignificant unprofitability requiring external funding.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eCompetitive Advantage: Hinges on Next Steps\u003c\/h3\u003e\n\u003cp\u003eThe competitive advantage is currently \u003cstrong\u003etemporary\u003c\/strong\u003e. The FDA has explicitly stated that the SIERRA trial alone is not adequate for BLA filing; they require an additional Phase 3 randomized head-to-head trial demonstrating an overall survival benefit. The advantage hinges entirely on Actinium securing a partner to fund and execute this next trial and achieving timely FDA approval following that data readout. If onboarding takes 14+ days for a partner agreement, the timeline for this advantage erodes.\u003c\/p\u003e\n\u003cp\u003eKey factors determining the advantage duration:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSecure U.S. strategic partner.\u003c\/li\u003e\n\u003cli\u003eFinalize FDA-requested head-to-head trial design.\u003c\/li\u003e\n\u003cli\u003eAchieve positive overall survival data.\u003c\/li\u003e\n\u003cli\u003eMaintain patent protection until $\\mathbf{2037}$.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eActinium Pharmaceuticals, Inc. (ATNM) - VRIO Analysis: Actimab-A Clinical Pipeline in AML\/Myeloid Malignancies\n\u003c\/h2\u003e\n\u003cp\u003e\nActimab-A is a CD33 targeting radiotherapeutic utilizing Actinium-225 (Ac-225).\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue: Positions the drug as a potential backbone therapy in Acute Myeloid Leukemia (AML) through combination trials, including one with the National Cancer Institute (NCI).\u003c\/h\u003e\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCombination\/Setting\u003c\/th\u003e\n\u003cth\u003eKey Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Comparison\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eActimab-A + CLAG-M (r\/r AML)\u003c\/td\u003e\n\u003ctd\u003eMedian Overall Survival (OS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18.4 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePatients with 1 or 2 lines of prior therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHistorical CLAG-M Alone (pre-Venetoclax)\u003c\/td\u003e\n\u003ctd\u003eMedian OS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13.3 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHistorical data comparison\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActimab-A + CLAG-M (Prior Venetoclax)\u003c\/td\u003e\n\u003ctd\u003eMRD Negativity Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIn patients with prior Venetoclax therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFrontline AML Trial (NCI CRADA)\u003c\/td\u003e\n\u003ctd\u003eCombination Agents\u003c\/td\u003e\n\u003ctd\u003eActimab-A + Venetoclax + ASTX-727\u003c\/td\u003e\n\u003ctd\u003eFirst-ever triplet combination using targeted radiotherapy as backbone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity: Its use as a mutation-agnostic alpha-emitter backbone is a differentiated approach in AML treatment.\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eActimab-A utilizes Actinium-225 (Ac-225), a potent alpha-emitter payload.\u003c\/li\u003e\n\u003cli\u003eActimab-A + CLAG-M demonstrated efficacy in patients with high-risk features: \u003cstrong\u003e52%\u003c\/strong\u003e had TP53 mutations.\u003c\/li\u003e\n\u003cli\u003eMRD Negativity Rate in TP53 mutation patients with Actimab-A + CLAG-M: \u003cstrong\u003e83.3%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAddressable Market (AML\/MDS in U.S. and EU5): Over \u003cstrong\u003e100,000 patients\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability: The specific combination regimens and ongoing CRADA are somewhat difficult to replicate quickly.\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDevelopment includes a Cooperative Research and Development Agreement (CRADA) with the \u003cstrong\u003eNational Cancer Institute (NCI)\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe frontline trial under CRADA (NCT06802523) plans to enroll approximately \u003cstrong\u003e48 patients\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eActimab-A + CLAG-M resulted in \u003cstrong\u003e71%\u003c\/strong\u003e of eligible patients receiving a bone marrow transplant (BMT), with a median OS of \u003cstrong\u003e24.05 months\u003c\/strong\u003e in this subgroup.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization: Clinical data readouts are expected by year-end 2025, indicating active management of the program.\u003c\/h\u003e\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eFrontline AML Trial (NCI CRADA) Initial Data Expected\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2H:2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFrontline AML Trial Estimated Completion Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSeptember 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Data (As of 30-Sep-2025) Trailing 12-Month Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$90K\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Data (As of June 30, 2025) Cash and Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$59.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage: Temporary; sustained advantage depends on delivering superior clinical outcomes versus standard-of-care combinations.\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eActimab-A + CLAG-M median OS of \u003cstrong\u003e18.4 months\u003c\/strong\u003e compares favorably to historical CLAG-M alone median OS of \u003cstrong\u003e13.3 months\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePatients failing Venetoclax typically have median survival of \u003cstrong\u003e2.4 – 4.6 months\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eStock Price (As of 14-Nov-2025): \u003cstrong\u003e$1.27\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMarket Capitalization (As of 14-Nov-2025): \u003cstrong\u003e$39.6M\u003c\/strong\u003e with \u003cstrong\u003e31.2M\u003c\/strong\u003e shares outstanding.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eActinium Pharmaceuticals, Inc. (ATNM) - VRIO Analysis: ATNM-400 Preclinical Efficacy in Solid Tumors\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDemonstrates potent, pan-tumor preclinical activity across prostate, NSCLC, and breast cancer, including overcoming resistance to established therapies. Specific efficacy metrics include:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIndication\/Comparison\u003c\/th\u003e\n\u003cth\u003eEfficacy Metric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProstate Cancer vs. Pluvicto ($\\text{Lu-177-PSMA-617}$)\u003c\/td\u003e\n\u003ctd\u003eImproved overall survival and tumor control in resistant models\u003c\/td\u003e\n\u003ctd\u003eContinued tumor control and potent cell killing after Pluvicto stops working\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProstate Cancer + Enzalutamide\u003c\/td\u003e\n\u003ctd\u003eComplete tumor cures in animal models\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e40%\u003c\/strong\u003e complete cures in tumor-bearing animals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNSCLC vs. Osimertinib (EGFR TKI)\u003c\/td\u003e\n\u003ctd\u003eTumor Growth Inhibition (TGI)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3-5 times greater\u003c\/strong\u003e TGI compared to osimertinib in EGFR-mutant models\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBreast Cancer (HR+\/HER2+) vs. Standard of Care\u003c\/td\u003e\n\u003ctd\u003eTumor Growth Inhibition (TGI)\u003c\/td\u003e\n\u003ctd\u003eTGI \u003cstrong\u003eexceeding 100%\u003c\/strong\u003e at higher doses in certain models\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe ATNM-400 target is directly implicated in tumor progression, survival signaling, and resistance to ARPI therapy, unlike PSMA-targeted agents.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePreclinical data showing superior efficacy over current standards in resistant models is rare and highly attractive. The mechanism is differentiated:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTargets a \u003cstrong\u003enon-PSMA\u003c\/strong\u003e protein overexpressed in castration-resistant prostate cancer (CRPC).\u003c\/li\u003e\n\u003cli\u003eMaintains efficacy in PSMA-low or PSMA-resistant disease, a major limitation of $\\text{177Lu-PSMA-617}$ (Pluvicto).\u003c\/li\u003e\n\u003cli\u003eUtilizes the alpha-emitter Actinium-225 ($\\text{Ac-225}$), which is noted as being \u003cstrong\u003e$\\sim 4-8$x more biologically lethal per cell\u003c\/strong\u003e than diffuse, low-energy external beam radiotherapy beams.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe specific antibody-radioconjugate design and target are proprietary, making direct imitation hard. The company is building infrastructure to support this differentiation:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe therapy is a first-in-class Actinium-225 ($\\text{Ac-225}$) antibody radioconjugate designed to deliver potent alpha-particle radiation.\u003c\/li\u003e\n\u003cli\u003eActinium is establishing in-house radiopharmaceutical manufacturing infrastructure in \u003cstrong\u003e2025\u003c\/strong\u003e to leverage its proprietary \u003cstrong\u003eActinium-225 cyclotron manufacturing technology\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company's intellectual property portfolio is comprised of approximately \u003cstrong\u003e240\u003c\/strong\u003e issued patents and pending applications worldwide as of August 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company is prioritizing this lead solid tumor program and presenting data at major 2025 conferences, indicating resource allocation. Financial context as of September 30, 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and Equivalents: \u003cstrong\u003e$53.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Loss for the nine months ended September 30, 2025: \u003cstrong\u003e$27.95 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eData presentations scheduled for major 2025 scientific meetings, including the San Antonio Breast Cancer Symposium (SABCS) on December \u003cstrong\u003e11, 2025\u003c\/strong\u003e, and the Prostate Cancer Foundation (PCF) Scientific Retreat (October \u003cstrong\u003e23 – 25, 2025\u003c\/strong\u003e).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained, provided the preclinical promise translates into positive human clinical data, supported by IP. The potential market scale is substantial, as evidenced by competitor performance:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe active agent in Pluvicto ($\\text{177Lu-PSMA-617}$) generated sales of \u003cstrong\u003e$1.39 billion\u003c\/strong\u003e in 2024.\u003c\/li\u003e\n\u003cli\u003eThe target antigen for ATNM-400 continues to be expressed at a high level even after Pluvicto treatment, suggesting sustained utility.\u003c\/li\u003e\n\u003cli\u003eNSCLC therapies that ATNM-400 demonstrated superior efficacy against generated sales of over \u003cstrong\u003e$7.0 billion\u003c\/strong\u003e in 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eActinium Pharmaceuticals, Inc. (ATNM) - VRIO Analysis: Proprietary Actinium-225 (Ac-225) Production Technology\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eOffers the potential to produce the critical alpha-emitter isotope Ac-225 at an expected cost \u003cstrong\u003e10 to 20 times lower\u003c\/strong\u003e than current material, with high purity (greater than or equal to \u003cstrong\u003e99.8%\u003c\/strong\u003e).\u003c\/p\u003e\n\u003cp\u003eFor a program treating \u003cstrong\u003e1,000\u003c\/strong\u003e patients per year, this translates into cost savings of greater than \u003cstrong\u003e$10 million\u003c\/strong\u003e each year.\u003c\/p\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eLow-cost, high-yield, in-house Ac-225 production via cyclotron is extremely rare in the industry.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThis know-how is protected by intellectual property and is very difficult and capital-intensive to replicate.\u003c\/p\u003e\n\u003cp\u003eIntellectual property portfolio includes \u003cstrong\u003e5\u003c\/strong\u003e issued U.S. patents and \u003cstrong\u003e49\u003c\/strong\u003e issued international patents related to the production method.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe company plans to commence the build-out of its own manufacturing facility in the \u003cstrong\u003esecond half of 2025\u003c\/strong\u003e to leverage this.\u003c\/p\u003e\n\u003cp\u003eThe company has deployed technologies and capabilities supported by approximately \u003cstrong\u003e230\u003c\/strong\u003e issued and pending patents worldwide.\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained; this cost and supply advantage is a fundamental barrier to entry for competitors.\u003c\/p\u003e\n\u003cp\u003eThe technology provides an end-to-end solution with demonstrated commercial scalability up to \u003cstrong\u003e100 mCi\u003c\/strong\u003e per batch.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecification\u003c\/td\u003e\n\u003ctd\u003eValue\/Metric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated COGS (Cyclotron Facility)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$650 - $1,000 \/ mCi\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadioisotopic Purity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e99.8%\u003c\/strong\u003e with no long-lived contaminants\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadiochemical Purity\u003c\/td\u003e\n\u003ctd\u003eGreater than \u003cstrong\u003e99%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRa-226 Target Irradiation Capacity\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e100 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIrradiation Time per Cycle\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e120 to 150 h\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCyclotron Energy\u003c\/td\u003e\n\u003ctd\u003eMedium energy (approximately \u003cstrong\u003e20 MeV\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eActinium Pharmaceuticals, Inc. (ATNM) - VRIO Analysis: Radiopharmaceutical Manufacturing and Supply Chain Experience\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Proven ability to manage the complex logistics of short half-life radiotherapeutics, having delivered over \u003cstrong\u003e500 doses\u003c\/strong\u003e for \u003cstrong\u003e18 clinical trials\u003c\/strong\u003e at \u003cstrong\u003e45 large cancer hospitals\u003c\/strong\u003e without missing a dose.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Deep, practical experience in 'just-in-time' delivery and administration coordination for radiotherapeutics is uncommon. This operational history is supported by clinical data from multiple assets:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eActimab-A single agent Phase 1\/2 trial produced a \u003cstrong\u003e69%\u003c\/strong\u003e remission rate (CR, CRi, CRp) at high doses in newly diagnosed AML patients.\u003c\/li\u003e\n\u003cli\u003eActimab-A in combination with CLAG-M showed an \u003cstrong\u003e86%\u003c\/strong\u003e complete remission (CR\/CRi) rate in the second cohort at the 0.50 uCi\/kg dose.\u003c\/li\u003e\n\u003cli\u003eActimab-A has been developed in clinical development involving approximately \u003cstrong\u003e150 patients\u003c\/strong\u003e treated over \u003cstrong\u003e6 clinical trials\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: This is tacit knowledge gained through years of operational execution, not easily written down or bought. The company's financial strength to support these operations includes a Current Ratio of \u003cstrong\u003e10.25\u003c\/strong\u003e. As of September 30, 2024, Cash and cash equivalents were approximately \u003cstrong\u003e$78.6 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: This core competency directly supports the clinical advancement of all pipeline assets. The operational excellence underpins the data generated across the portfolio:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset\/Metric\u003c\/td\u003e\n\u003ctd\u003eClinical\/Preclinical Data Point\u003c\/td\u003e\n\u003ctd\u003eValue\/Result\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIomab-B (SIERRA Trial)\u003c\/td\u003e\n\u003ctd\u003ePatients Enrolled\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e153\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIomab-B (SIERRA Trial)\u003c\/td\u003e\n\u003ctd\u003e6-Month dCR Rate vs. Control\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e22%\u003c\/strong\u003e vs \u003cstrong\u003e0%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIomab-B (SIERRA Trial)\u003c\/td\u003e\n\u003ctd\u003eEngraftment Rate vs. Control\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e100%\u003c\/strong\u003e vs \u003cstrong\u003e18%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATNM-400 (Preclinical)\u003c\/td\u003e\n\u003ctd\u003eTumor Growth Inhibition (Single Dose)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e99.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained; operational excellence in a niche field is a hard-won advantage. The company's intellectual property portfolio includes approximately \u003cstrong\u003e230 patents and patent applications\u003c\/strong\u003e related to targeted radiotherapies and Ac-225 manufacture.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eActinium Pharmaceuticals, Inc. (ATNM) - VRIO Analysis: Broad Intellectual Property (IP) Portfolio\n\u003c\/h2\u003e\n\u003cp\u003eThe Intellectual Property (IP) portfolio forms a foundational layer of competitive resources for Actinium Pharmaceuticals, Inc., covering core technologies in Antibody Radiation-Conjugates (ARCs) and Actinium-225 (Ac-225) based therapies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Protection for key drug candidates and manufacturing processes, encompassing approximately \u003cstrong\u003e250\u003c\/strong\u003e issued and pending patents worldwide. This IP estate covers ARC generation, composition of matter, formulations, and methods of administration for solid and liquid cancers, as well as radionuclide production, including the manufacturing of Ac-225.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e A portfolio of this size in a specialized field like targeted radiotherapy is significant. The IP underpins the development of clinical and preclinical assets, including Actimab-A and ATNM-400.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Patents provide legal barriers to entry. Litigation risk exists, as evidenced by securities class action lawsuits related to the Iomab-B BLA filing process, which covered the period up to August 2, 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The IP underpins the value of all pipeline assets, from Actimab-A to ATNM-400. The company is deploying this IP to develop targeted and next-generation radiotherapies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as long as the patents remain valid and enforceable.\u003c\/p\u003e\n\n\u003cp\u003eThe following table details key statistical and financial data related to the assets supported by the IP portfolio:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\/Metric\u003c\/th\u003e\n\u003cth\u003eAssociated Data\/Value\u003c\/th\u003e\n\u003cth\u003eContext\/Endpoint\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Issued\/Pending Patents (Latest Confirmed)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e230\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of March 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActimab-A Patient Exposure\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e150\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003eTreated across 6 clinical trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActimab-A ORR (Recommended Phase 2 Dose)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e83%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIn combination with CLAG-M in r\/r AML\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATNM-400 Preclinical Efficacy\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e99.8%\u003c\/strong\u003e tumor growth inhibition\u003c\/td\u003e\n\u003ctd\u003eAchieved with a single \u003cstrong\u003e40 µCi\/kg\u003c\/strong\u003e dose in one prostate cancer model\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePluvicto (Novartis) 2024 Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.39 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMarketed radiotherapy for prostate cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXtandi (Enzalutamide) 2024 Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.9 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAndrogen receptor inhibitor for prostate cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAggregate Market Value (Non-affiliates)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$226,015,477\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommon Stock Outstanding\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e31,195,891\u003c\/strong\u003e shares\u003c\/td\u003e\n\u003ctd\u003eAs of March 28, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe IP portfolio specifically covers technologies integral to the pipeline:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eActimab-A:\u003c\/strong\u003e Leverages the Ac-225 payload, showing a \u003cstrong\u003e12-month\u003c\/strong\u003e median Overall Survival (OS) and \u003cstrong\u003e53%\u003c\/strong\u003e 1-year OS in a trial arm.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eATNM-400:\u003c\/strong\u003e Targets a non-PSMA receptor in prostate cancer, with preclinical data showing superior efficacy to Pluvicto®.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIomab-ACT:\u003c\/strong\u003e Next-generation conditioning candidate for cell and gene therapies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eManufacturing IP:\u003c\/strong\u003e Includes patents related to the manufacture of the isotope Ac-225 in a cyclotron.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eActinium Pharmaceuticals, Inc. (ATNM) - VRIO Analysis: Iomab-ACT for Cell \u0026amp; Gene Therapy Conditioning\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eIomab-ACT for Cell \u0026amp; Gene Therapy Conditioning\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eTargets the rapidly growing cell and gene therapy market, offering a differentiated, targeted conditioning agent beyond standard chemotherapy.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe global cell and gene therapy market size was valued at $24.84 billion in 2024 and is projected to reach $166.9 billion by 2034.\u003c\/li\u003e\n\u003cli\u003eSeven approved CAR-T therapies generated over $4 billion in sales in 2024.\u003c\/li\u003e\n\u003cli\u003eOver 150,000 patients are diagnosed annually with conditions treated by approved CAR-T therapies (lymphomas, leukemias, multiple myeloma).\u003c\/li\u003e\n\u003cli\u003eIomab-ACT is intended to replace non-targeted chemotherapeutic agents such as Fludarabine and Cyclophosphamide (Flu\/Cy).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eA targeted conditioning agent specifically for CAR-T and Sickle Cell Disease (SCD) addresses a clear market gap.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIomab-ACT is currently being studied in a sickle cell disease (SCD) transplant trial led by Columbia University.\u003c\/li\u003e\n\u003cli\u003eIomab-ACT is described as the only CD45 ARC for targeting conditioning in clinical development.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eThe specific construct is protected, but the concept of targeted conditioning is an emerging field.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eActinium holds over 230 patents and patent applications.\u003c\/li\u003e\n\u003cli\u003eA family of issued composition of matter patents covering Iomab-ACT extends into 2037.\u003c\/li\u003e\n\u003cli\u003eU.S. Patent No. 11,912,780 extends patent protection over Iomab-ACT aspects until 2040.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eInitiation of a commercial CAR-T trial and SCD trial data expected in the second half of 2025 shows focus.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe commercial CAR-T trial at the University of Texas Southwestern Medical Center initiated patient enrollment in 1Q 2025.\u003c\/li\u003e\n\u003cli\u003eProof-of-concept clinical data from the commercial CAR-T trial is expected in the second half of 2025.\u003c\/li\u003e\n\u003cli\u003eThe Iomab-ACT sickle cell disease trial was expected to initiate in 1H:2025.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents were approximately $78.6 million as of September 30, 2024, expected to fund operations into 2027.\u003c\/li\u003e\n\u003cli\u003eActinium Pharmaceuticals' Market Capitalization as of late November 2025 was $43.06M or $45.23M.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary; the first-mover advantage in this specific application is strong but could be eroded by fast-following competitors.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCAR-T therapies are forecasted to reach $12 billion in annual sales in 2030.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eContext\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIomab-ACT CAR-T Data Expected\u003c\/td\u003e\n\u003ctd\u003eSecond Half of 2025\u003c\/td\u003e\n\u003ctd\u003eProof-of-Concept Clinical Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIomab-ACT SCD Trial Initiation\u003c\/td\u003e\n\u003ctd\u003e1H:2025\u003c\/td\u003e\n\u003ctd\u003eExpected Initiation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS CAR-T Sales\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e$4 Billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eForecasted CAR-T Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12 Billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIomab-ACT Patent Expiration (US)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2040\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSpecific U.S. Patent Term\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany Cash Runway\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany Market Cap\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$45.23 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eActinium Pharmaceuticals, Inc. (ATNM) - VRIO Analysis: Financial Stability and Cash Runway\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The company reports a cash runway extending into the \u003cstrong\u003esecond half of 2026\u003c\/strong\u003e based on \u003cstrong\u003e$84.3 million\u003c\/strong\u003e of cash on hand as of March 27, 2024, providing time to reach critical clinical milestones without immediate dilution pressure.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e A multi-year runway is valuable, especially for a late-stage clinical company. The cash position as of September 30, 2025, was \u003cstrong\u003e$53.4 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Financial resources are quantifiable and can be replicated through financing, but the current runway is a present fact. Net cash used in operating activities for the year ended December 31, 2024, was \u003cstrong\u003e$33.1 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e This stability allows management to focus on R\u0026amp;D execution rather than constant fundraising. Total Liabilities as of September 30, 2025, were \u003cstrong\u003e$42.4 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the runway is finite and will require replenishment or a successful partnership\/sale. Total Assets as of September 30, 2025, were \u003cstrong\u003e$56.2 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eKey Financial Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003cth\u003eAmount (USD)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$59,928 thousand\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Equivalents\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$53.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash on Hand\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2023\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$76.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash on Hand\u003c\/td\u003e\n\u003ctd\u003eMarch 27, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$84.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash on Hand\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$72.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Used in Operating Activities\u003c\/td\u003e\n\u003ctd\u003eYear Ended December 31, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$33.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Used in Operating Activities\u003c\/td\u003e\n\u003ctd\u003eNine Months Ended September 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term License Revenue Deferred\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$35.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOperational Cash Flow Summary:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash flows used in operating activities for the six months ended June 30, 2025: \u003cstrong\u003e$(12,966) thousand\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet loss for the nine months ended September 30, 2025: \u003cstrong\u003e$27.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet loss for the three months ended June 30, 2025: \u003cstrong\u003e$(6,878) thousand\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFinancing activities provided \u003cstrong\u003e$24,722 thousand\u003c\/strong\u003e for the six months ended June 30, 2024.\u003c\/li\u003e\n\u003cli\u003eFinancing activities provided \u003cstrong\u003e$29.3 million\u003c\/strong\u003e in gross proceeds from stock sales for the year ended December 31, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eCapital Structure Data:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eShares Outstanding as of November 14, 2025: \u003cstrong\u003e31,195,891\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Liabilities as of September 30, 2025: \u003cstrong\u003e$42.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Stockholders' Equity as of September 30, 2025: \u003cstrong\u003e$13.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eActinium Pharmaceuticals, Inc. (ATNM) - VRIO Analysis: Targeted Radiotherapy Technology Platform (ARC)\n\u003c\/h2\u003e\n\n\u003cp\u003eThe ARC platform underpins the company's targeted radiotherapies, leveraging Actinium-225 (Ac-225) alpha-emitter technology.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe underlying Antibody Radioconjugate (ARC) platform allows for the systematic development of next-generation therapies by pairing different antibodies with radioisotopes (like Ac-225).\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe platform supports the development of Actimab-A (targeting CD33), Iomab-B (conditioning agent), and ATNM-400 (non-PSMA prostate cancer radiotherapy).\u003c\/li\u003e\n\u003cli\u003eATNM-400 demonstrated superior efficacy over 177Lu-PSMA-617 and enzalutamide in head-to-head preclinical comparisons.\u003c\/li\u003e\n\u003cli\u003eAc-225 delivers high-linear-energy-transfer alpha particles, inducing irreparable double-strand DNA breaks, offering superior potency over beta emitters like Lutetium-177 (177Lu).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe platform's ability to effectively deploy potent alpha-emitters like Ac-225 is a specialized capability.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTo the knowledge of the company, Actimab-A is the only CD33 targeting radiotherapy in clinical development.\u003c\/li\u003e\n\u003cli\u003eActinium holds approximately 250 patents and patent applications, including several related to the manufacture of the isotope Ac-225 in a cyclotron.\u003c\/li\u003e\n\u003cli\u003eAs of 2023, the company had 17 Active Patents in Radiopharmaceutical Technologies across the United States, Europe, and Japan.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe platform's architecture and know-how are proprietary and built over time.\u003c\/p\u003e\n\u003cp\u003eThe platform's proprietary nature is supported by its intellectual property portfolio:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIP Category\u003c\/th\u003e\n\u003cth\u003eCount (as of 2023)\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadiopharmaceutical Technologies Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eActive\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAc-225 Platform Innovations Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePending Applications (PCT)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThis platform supports the entire pipeline, linking Actimab-A, Iomab-B, and ATNM-400 under one technological umbrella.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company has established manufacturing infrastructure activity in 2025, including its Actinium-225 cyclotron manufacturing technology, to support its expanding clinical pipeline.\u003c\/li\u003e\n\u003cli\u003eStrategic partnerships have contributed approximately $12.5 million in research funding as of 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained; a proven, versatile platform is a core, hard-to-replicate asset.\u003c\/p\u003e\n\u003cp\u003eThe platform supports multiple potential blockbuster opportunities:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eActimab-A in myeloid malignancies and solid tumors.\u003c\/li\u003e\n\u003cli\u003eIomab-ACT for cell and gene therapy conditioning.\u003c\/li\u003e\n\u003cli\u003eATNM-400 in prostate cancer.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eFinance\u003c\/h3\u003e\n\u003cp\u003eThe 13-week cash flow projection incorporates expected 2H 2025 data milestones by Friday. The projection basis utilizes the latest reported liquidity and expected value-inflection points.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount (as of Sep 30, 2025)\u003c\/th\u003e\n\u003cth\u003eContext\/Projection Input\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$53.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eManagement expects current resources sufficient for operations for at least 12 months from filing.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Used in Operating Activities (9M 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCash runway expected to last into mid-2027.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Current Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.834 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSupports a Working Capital of $54.4 million (Current Assets) minus Current Liabilities.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Data Readouts (2H 2025)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eClinical proof of concept data for Actimab-A solid tumors; Initial clinical data from Actimab-A triplet in frontline AML (year-end 2025); Iomab-ACT commercial CAR-T trial data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516117704853,"sku":"atnm-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/atnm-vrio-analysis.png?v=1740141482","url":"https:\/\/dcf-model.com\/fr\/products\/atnm-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}